According to a resolution passed by the Cabinet of Ministers, the relative value of codes 100710 and 100715—which pertain to sentinel lymph node excision during mastectomy procedures—will increase by approximately 50K starting from the beginning of 1404.
These procedures, typically performed with the aid of specialized equipment such as GammaProbes, are now subject to updated tariff regulations. This important revision responds to longstanding concerns about the historically low tariff associated with this specialized service.
In this context, the GammaProbe developed by Parto Negar Persia company, an innovative tech company and the only domestic producer of this highly sensitive technology, has played a pivotal role in advancing the quality of breast cancer surgeries.
It is also worth noting that code 100711, designated for sentinel lymph node resection, may be used alongside the aforementioned codes to provide more comprehensive service coverage.
This update represents a significant step forward in supporting indigenous technologies and in reinforcing the role of nuclear medicine in cancer treatment pathways.
